1. Pink Sheet
  2. >>Legislation

No Room For Error: China Proposes Hefty Fines On Quality Violations In Drug Law Overhaul

 
• By Brian Yang

A proposed revision to China's Drug Administration Law will crack down on GMP violations with hefty fines, while a dedicated law proposes additional scrutiny over imported vaccines.

Chinese flag
CHINA PROPOSES HEFTY FINES FOR DRUG QUALITY VIOLATIONS. • Source: Shutterstock

With potential fines as high as 30 times the revenues obtained from illegal operations, China is stepping up a crackdown on drug product quality violations and counterfeit products.

China’s legislative body, the standing committee of the National People’s Congress (NPC), is reviewing the second draft of a revised Drug Administration Law (DAL)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Pink Sheet

Global Pharma Guidance Tracker - April 2025

 
• By Vibha Sharma and Anabel Costa-Ferreira

Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Medicare Negotiation Does Not Violate Due Process, Appeals Court Rules, Other Suits At Risk

 
• By Cathy Kelly

Decision in AstraZeneca’s lawsuit against the Health and Human Services Department is a precedent-setting victory for the government and a blow to manufacturer efforts to block the price negotiation program.

Keep Talking: US FDA’s Beleaguered Biologics Center Remains Vital To Regenerative Medicine

 
• By Bridget Silverman

Advisory committee for Capricor’s deriamocel planned, regenerative medicine advanced therapy designations proliferate for osteoarthritis, and the ranks of dual RMAT/breakthrough therapy designation holders grow.